靶向免疫检查点 B7-H3 对肿瘤的免疫治疗作用

B7-H3, also known as CD276, is a new immune checkpoint discovered in recent years and belongs to the B7 superfamily. It has low or no expression in normal human tissues, but abnormal expres- sion in immune cells and tumor tissues. B7-H3 is related to tumor immunotherapy and plays a dual role of co-stimulation / co-inhibition in tumor microenvironment (TME). Therefore, targeting B7-H3 can achieve accurate tumor immunotherapy, thus enhancing anti-tumor immune responses. As the immune function of B7-H3 in tumors has been widely revealed, targeted drugs have also been developed and have entered preclinical and clinical trials. However, the different forms and functions of B7-H3 in human body are still controversial, the human origin structure has not been analyzed, and its potential receptor has not been confirmed. In this paper, the structure and function of B7-H3, its physiological role in tumor immu- nity and the research progress of targeted therapy are reviewed. In the future, it is necessary to further explore the exact evidence of B7-H3 in tumor immunotherapy and the challenges and limitations of exist- ing therapies, in order to provide new directions and approaches for drug development targeting B7-H3.